Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. […]
Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Ariana, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas
The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases.
Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.
Paris and Boston, April 17th 2020. Ariana® Pharma, a leading digital health company announced today the publication of the first reported genome-wide search for biomarkers associated with drug response in Alzheimer’s disease in the Alzheimer’s & Dementia: Translational Research & Clinical Interventions journal. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, […]
Big Data analysis of over 125 Million patient hospitalization records using Ariana’s data analytics and AI platform identifies significant factors increasing Case Fatality Rates Paris and Boston, November 7th 2019. Ariana Pharma, a leading digital health Company announced the publication of an influenza Real World analysis in collaboration with Sanofi-Pasteur. Influenza-related mortality for hospitalized patients […]
Ariana’s KEM® Artificial Intelligence technology identified immunological changes, which are early indicators of clinical effects, for selected groups of patients in a first-in-human Phase 1b study. The potential for a selection biomarker in patients receiving this therapy transforms design options for Imcyse’s future clinical trials in T1D and additional indications. On August 27th 2019, Imcyse, […]